Vaso Corp Stock Price, News & Analysis

Vaso (OTCQX: VASO) reported third-quarter 2025 results for the three months ended September 30, 2025, with total revenue of $22.7 million, up 9.1% year‑over‑year. Gross profit rose to $13.9 million, an increase of 18.2%, and the company recorded net income of $1.7 million versus a net loss of $1.2 million in Q3 2024, a $2.9 million improvement. Adjusted EBITDA was $1.6 million versus negative $1.2 million a year earlier. Cash and cash equivalents were $34.9 million at quarter end, and operating cash flow for the first nine months of 2025 was $9.0 million versus $3.6 million in the prior-year period.

All three business segments contributed to revenue growth; professional sales services led with an 18.7% increase. SG&A rose modestly while deferred and subscription revenues continued to trend upward.

Vaso Corporation (OTCQX: VASO), a MedTech company, reported its Q2 2025 financial results with revenue of $20.0 million, slightly down 1.3% from $20.2 million in Q2 2024. The company posted a net loss of $197,000 compared to a net income of $1.2 million in the same period last year.

The company's professional sales service segment experienced a 4.0% decline, while the IT segment saw a 0.9% increase. Notable metrics include record-high deferred revenue of $38.1 million (up from $31.7 million YoY), gross profit of $11.8 million (down 2.9%), and strong cash position of $32.6 million. Operating cash flow for Q2 2025 was $6.8 million, demonstrating robust cash generation despite operational challenges.

The professional sales service segment saw a 7.1% revenue increase, while the IT segment grew by 1.6%. The equipment segment experienced a slight decline of 3.6%. Total deferred revenue reached $35.4 million, up 12.7% year-over-year, providing revenue stability and financial visibility.

The company maintained a strong balance sheet with $25.3 million in cash as of March 31, 2025, which improved to approximately $30.5 million by May 9, 2025. Despite increased market uncertainties, management remains cautiously optimistic about 2025, citing historically stronger performance in later quarters.

Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, up 7% year-over-year. The company's Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all business segments.

Key financial highlights for 2024:

• Gross profit increased 2.9% to $52.1 million
• Net income decreased to $1.0 million from $4.8 million in 2023
• Operating cash flow of $3.3 million
• Cash and equivalents of $26.3 million
• Deferred revenue grew 8% to $34.9 million

The decline in net income was primarily attributed to higher operating expenses, including investments in new programs and strategic activities. SG&A expenses increased 8.7% to $49.0 million, representing 56.5% of revenue.

Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, a 7% increase from 2023. Despite revenue growth, net income decreased to $1.3 million from $4.8 million in 2023 due to higher operating expenses.

Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all segments: IT segment up 13.6% to $11.1 million, professional sales service up 31.2% to $15.0 million, and equipment segment up 31% to $921 thousand. The company maintained strong cash position with $26.3 million in cash and equivalents, while generating $3.3 million in operating cash flow during 2024.

Total deferred revenue grew 8% to $34.9 million, while adjusted EBITDA decreased to $1.4 million from $5.1 million in 2023. SG&A expenses increased 7.9% to $48.6 million, primarily due to higher personnel costs and expenses related to a terminated business combination transaction with Achari.

Vaso (OTCQX: VASO) announced key executive leadership changes effective January 1, 2025. Jane Moen, who has served as a Director since 2020, was appointed Chief Operating Officer while retaining her role as President of VasoHealthcare. Jonathan Newton was promoted to Chief Financial Officer from Co-Chief Financial Officer, with Michael Beecher transitioning to a financial and investor relations advisory role.

Additionally, Edgar Rios, who has served as an independent Director since 2011, was elected Vice Chairman of the Board of Directors and will continue as Chairman of the Board's Audit Committee. The company also appointed Kimberly Decker of Barley Snyder LLP as new corporate and securities outside counsel.

CEO Dr. Jun Ma emphasized these changes align with Vaso's human capital mission and 2025 strategy, focusing on organic growth across their diversified portfolio in human capital, MedTech, and information technology businesses.

Vaso (OTCQX: VASO), a company focused on human capital, information technology, and MedTech sectors, has released a shareholder and employee letter on December 16, 2024. The letter outlines the company's achievements throughout the year and presents strategic developments and priorities for 2025. The communication covers operational developments, product updates, financial performance, and thought-leadership initiatives, with details available on the company's website.

Vaso (OTCQX: VASO) reported Q3 2024 financial results with revenue of $20.8 million, up 7% from $19.4 million in Q3 2023, driven by growth in network services. However, the company recorded an operating loss of $1.4 million compared to operating income of $907,000 in Q3 2023. The company maintains a strong balance sheet with $26.8 million in cash and investments, and generated $3.6 million in operating cash flow during the first nine months. Deferred revenue increased by $1.4 million to $33.1 million. The net loss for Q3 2024 was $1.2 million, compared to net income of $1.2 million in Q3 2023, primarily due to business combination costs of $1.5 million.

Vaso (OTCQX: VASO) has announced the termination of its Business Combination Agreement with Achari Ventures Holdings Corp. I. The company, based in Plainview, N.Y., made this decision on September 18, 2024. Vaso stated that it will continue to pursue opportunities to enhance stockholder value through various means, including:

• Internal growth
• New partnerships
• Strategic investments

The company's focus will remain on medical and IT service companies as it seeks to expand its business and create value for shareholders.